N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms-Reference-Cited by-同舟云学术

N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms

Published:2020-11-30 Issue:23 Volume:63 Page:14921-14936
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Yang Tao¹,Hu Mengshi¹,Chen Yong¹,Xiang Mingli¹,Tang Minghai¹,Qi Wenyan¹,Shi Mingsong¹,He Jun¹,Yuan Xue¹,Zhang Chufeng¹,Liu Kongjun¹,Li Jiewen¹,Yang Zhuang¹²,Chen Lijuan¹²^ORCID

Affiliation:

1. State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China

2. Chengdu Zenitar Biomedical Technology Co., Ltd., Chengdu 610041, China

Funder

National Natural Science Foundation of China

West China Hospital, Sichuan Univeristy

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c01488

Reference42 articles.

1. Myeloproliferative Neoplasms